ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0582

Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial

Vibeke Strand1, Kenneth Kalunian2, Barnabas Desta3, Caroline Seo4, Gabriel Abreu5, Raj Tummala3, Catharina Lindholm5 and Hussein Al-Mossawi6, 1Stanford University, Palo Alto, CA, 2University of California San Diego, La Jolla, CA, 3BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, 4BioPharmaceuticals Medical Evidence, AstraZeneca, Gaithersburg, MD, 5BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, 6BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom

Meeting: ACR Convergence 2023

Keywords: Biologicals, Patient reported outcomes, Randomized Trial, SF36, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 12, 2023

Title: (0582–0608) SLE – Treatment Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: SLE is a chronic disease that progressively reduces patients’ health-related quality of life.1 In a post hoc analysis of the TULIP trials, patients with SLE reported improvements in patient-reported outcome measures over 52 weeks.2 Here, we evaluated the long-term impact of anifrolumab treatment on the Short Form 36 Health Survey version 2 (SF-36v2) in patients receiving standard therapy from the placebo-controlled, phase 3 long-term extension (LTE) trial.3

Methods: Adult patients with moderate to severe SLE (1997 ACR criteria) who completed a 52-week TULIP-1 or TULIP-2 trial could enroll in the 3-year LTE study (NCT02794285). Patients included in this analysis were randomized to intravenous anifrolumab 300 mg or placebo every 4 weeks in TULIP-1/-2 and continued in the same treatment group in the LTE, in addition to standard therapy. Proportions of patients classified as responders (defined by positive changes in responses from baseline greater than or equal to the minimum clinically important differences [MCIDs]) in Physical and Mental Component Scores (PCS/MCS) and SF-36v2 individual domains (acute recall) were analyzed for each treatment group using a Cochran–Mantel–Haenszel approach from Weeks 52 to 208. MCIDs were defined as changes from baseline ≥2.5 for PCS and MCS scores and ≥5 for all SF-36v2 domains.2Patients with baseline PCS ≤73.01 and MCS ≤67.15 scores and those with each baseline SF-36v2 domain score ≤95 were included in each respective analysis. Domain scores were non-normalized and scaled from worst to best (0–100).

Results: The proportion of PCS responders treated with anifrolumab (n=257; Figure A) increased over time from 51% at Week 52 to 56% at Week 208, whereas the proportion of responders decreased in the placebo group (n=112; Figure B) from 45% to 38%. The proportion of MCS responders was sustained for patients on anifrolumab with a 1% increase over 3 years, but decreased by 10% for patients on placebo. Proportions of SF-36v2 responders treated with anifrolumab were generally maintained throughout the 3-year LTE period, with 47%–61% of patients reporting improved domain scores at Week 208. In all SF-36v2 domains except for General Health and Role Emotional, similar or higher proportions of anifrolumab-treated patients were responders at Week 208 compared with Week 52. In contrast, the proportions of responders receiving placebo decreased over time in all domains except Role Physical, ranging from 36%–56% at Week 208.

Conclusion: Patients with SLE treated with anifrolumab had sustained improvements in PCS, MCS, and most SF-36v2 individual domains over the 3-year LTE period. This was not observed in patients on standard therapy alone, despite the higher dropout rates and survivor bias observed in the placebo group.3 These results support the long-term benefit of anifrolumab on self-reported, clinically important, health status outcomes across multiple domains.

References:

1. Kaul A, et al. Nat Rev Dis Primers.2016;2:16039.
2. Strand V, et al. Lancet Rheumatol. 2022;4:e198–e207.
3. Kalunian KC, et al. Arthritis Rheumatol. 2023;75:253–65.

Supporting image 1

Figure. The Proportions of PCS, MCS and SF_36v2 by Domain Responder Patients by Treatment Group Throughout the TULIP-LTE Study. A) Anifrolumab 300 mg; B) Placebo.

CMH, Cochran–Mantel–Haenszel; GC, glucocorticoids; IFN, interferon; LTE, long-term extension; MCS, Mental Component Score; PCS, Physical Component Score; SF_36v2, Short Form 36 Health Survey version 2; TULIP, Treatment of Uncontrolled Lupus via the Interferon Pathway.

Percentages of responders were calculated using a stratified CMH approach (stratification factors: SLEDAI_2K score at screening [<10 points vs
≥10 points], Week 0 GC dose [<10 mg/day vs ≥10 mg/day] and type I IFN gene signature test result at screening [high vs low]).

Responders were defined as positive changes in responses from baseline greater than or equal to the minimum clinically important differences.


Disclosures: V. Strand: AbbVie, 2, Alpine Immune Sciences, 2, Alumis, 2, Amgen, 2, AstraZeneca, 2, Bayer, 2, Bioventus, 2, Blackrock, 2, Boehringer Ingelheim, 2, Bristol Myers Squibb, 2, Celltrion, 2, Citryll, 2, Ermium, 2, Genentech/Roche, 2, Gilead, 2, GlaxoSmithKline, 2, Horizon, 2, Inmedix, 2, Janssen, 2, Kiniksa, 2, Lilly, 2, Merck, 2, MiMedx, 2, Novartis, 2, Omeros, 2, Pfizer, 2, RAPT, 2, Regeneron, 2, R-Pharm, 2, Samsung, 2, Sandoz, 2, Sanofi, 2, Scipher, 2, Setpoint, 2, Sorrento, 2, Spherix, 2, Urica, 2, 4; K. Kalunian: AbbVie, 2, Amgen, 2, AstraZeneca, 2, Biogen, 2, Bristol-Myers Squibb, 2, Eli Lilly, 2, Genentech/Roche, 2, GlaxoSmithKline, 2, Janssen, 2, Pfizer, 2; B. Desta: AstraZeneca, 3; C. Seo: AstraZeneca, 3; G. Abreu: AstraZeneca, 3; R. Tummala: AstraZeneca, 3; C. Lindholm: AstraZeneca, 3; H. Al-Mossawi: AstraZeneca, 3.

To cite this abstract in AMA style:

Strand V, Kalunian K, Desta B, Seo C, Abreu G, Tummala R, Lindholm C, Al-Mossawi H. Evaluation of Anifrolumab Treatment Responses by the Short Form 36 Health Survey Version 2 in SLE: A Post Hoc Analysis of the Placebo-Controlled Phase 3 Long-Term Extension Trial [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/evaluation-of-anifrolumab-treatment-responses-by-the-short-form-36-health-survey-version-2-in-sle-a-post-hoc-analysis-of-the-placebo-controlled-phase-3-long-term-extension-trial/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/evaluation-of-anifrolumab-treatment-responses-by-the-short-form-36-health-survey-version-2-in-sle-a-post-hoc-analysis-of-the-placebo-controlled-phase-3-long-term-extension-trial/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology